Contineum Therapeutics, Inc. — Insider Transactions
Form 4 filings by directors, officers, and 10%+ shareholders
SEC rules require corporate insiders — including directors, executive officers, and any shareholder owning more than 10% of a company's shares — to report changes in their ownership within two business days of a transaction. These disclosures are filed as Form 4. Open-market purchases (code P) are generally considered the most meaningful signal, as insiders are spending their own money.
| Insider | Title | Type | Shares | Price | Value | Owns After | Date |
|---|---|---|---|---|---|---|---|
| Watkins Tim | CMO & Head of Development | Option Exercise | 3,611 | $4.50 | $16,250 | 3,611 | Dec 29, 2025 |
| Lorrain Daniel S. | Chief Scientific Officer | Sale | 4,170 | $12.23 | $50,999 | 164,392 | Dec 23, 2025 |
| Lorrain Daniel S. | Chief Scientific Officer | Sale | 1,010 | $16.02 | $16,180 | 168,562 | Nov 25, 2024 |
| Lorrain Daniel S. | Chief Scientific Officer | Sale | 99 | $17.05 | $1,688 | 169,572 | Nov 18, 2024 |
| Huhn Stephen L. | CMO & Sr VP, Clinical Dev. | Option Exercise | 12,800 | $1.01 | $12,928 | 12,800 | Aug 13, 2024 |
| Versant Vantage I, L.P. | — | C | 2,531 | — | — | 2,531 | Apr 9, 2024 |